Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dacomitinib in Advanced Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: A Single Center and Exploratory Study

NCT04504071 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT04504071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dacomitinib in Advanced Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: A Single Center and Exploratory Study
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 8, 2020
Completion date
December 1, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egf-r positive non-small cell lung cancer, non-small cell lung cancer metastatic